Company profile
Aeolus Pharmaceuticals, Inc.
OTC: AOLS · Healthcare · Drug Manufacturers - Specialty & Generic
#788 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 40
v0.1 · 5/100 weight · pillars only
↑ listing tenure, balance-sheet leverage · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$771.0k
Rev growth YoY (TTM)
-68.7%
Net income (FY)
-$3.6M
Employees
4
as of 2026-08-29
Market cap
$15.2k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.1M$2.1M2016
Net income-$3.6M-$3.6M2016
Operating income-$3.3M-$3.3M2016
Total assets$4.2M$4.2M2016
Liabilities$972.0k$972.0k2016
Equity$3.2M$3.2M2016
Revenue trend
FY2009 – FY2016 · USD
FY09
FY10
FY11
FY12
FY13
FY14
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aeolus Pharmaceuticals, Inc.’s revenue?
Aeolus Pharmaceuticals, Inc. booked $2.1M in FY2016 revenue, contracting 33% year over year — slower than 76% of Healthcare companies we track, at a -171.4% net margin.
Peers · Healthcare
Endexx Corporation——BNB Plus Corp.33DGeneLink, Inc.——Cyclerion Therapeutics, Inc.40DHealthLynked Corp.34D20/20 Biolabs Inc.29DNeighbors
Orange →Key facts
CEOChristopher Stanley
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMission Viejo, CA
ExchangeOTC: AOLS
Employees4
IPO date1996-02-02
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.